Please ensure Javascript is enabled for purposes of website accessibility

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

By Brian Orelli, PhD - Oct 31, 2019 at 9:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The sales figure for Vyndaqel shows the market potential for several smaller players' pipeline candidates.

The $79 million that Vyndaqel contributed to Pfizer's (PFE 0.34%) third-quarter revenue doesn't mean a whole lot to the pharmaceutical giant. It amounted to a whopping 0.6% of the company's overall revenue.

But you can bet that executives at Alnylam Pharmaceuticals (ALNY 3.86%), Akcea Therapeutics (AKCA), Ionis Pharmaceuticals (IONS 4.18%), and Eidos Therapeutics (EIDX) were checking sales of the drug after its first full quarter on the market in the U.S.

Vyndaqel has been approved in Europe for a few years, but hadn't gotten much uptake based on lackluster data, which was so weak the Food and Drug Administration held off on approving the drug.

But Pfizer stuck with Vyndaqel, eventually proving that the drug could help patients with cardiomyopathy caused by transthyretin (TTR)-mediated amyloidosis, a disease where the TTR protein aggregates in the heart and interferes with its function. Vyndaqel binds to TTR, stabilizing the protein and reducing the aggregation.

Doctor sitting at a table talking to a patient

Image source: Getty Images.


Alnylam sells Onpattro, an RNAi drug that reduces expression of the TTR protein by reducing levels of the intermediary mRNA. Akcea sells Tegsedi, which was developed by Ionis and also knocks down TTR mRNA levels. Eidos is developing AG10, which works in a similar fashion to Vyndaqel by stabilizing the TTR protein.

Onpattro and Tegsedi are approved for patients with the polyneuropathy form of the disease, in which the TTR protein aggregates in the nervous system, where it causes damage. While those approvals don't overlap with Vyndaqel's heart-focused approval, many patients have TTR amyloidosis in both places, so the drugs compete for a subset of patients. In fact, on Alnylam's first-quarter earnings call, management even noted that some patients in Europe were switching from Vyndaqel to Onpattro.

Edios' AG10 isn't on the market yet, but the company is keenly interested in how sales of Vyndaqel are going since the drug candidate is in a phase 3 study in patients with cardiomyopathy.

Alnylam recently started a phase 3 clinical trial testing Onpattro in patients with the cardiomyopathy version of the disease, and the biotech also has a second-generation version of Onpattro, called vutrisiran, that's being tested in the polyneuropathy and cardiomyopathy versions of the disease.

Likewise, Akcea and Ionis have a second-generation version of Tegsedi called AKCEA-TTR-LRx that they plan to test as a treatment for cardiomyopathy.

Work to do

Pfizer grabbing market share in the cardiomyopathy indication would clear create some challenges for Alnylam, Akcea, Ionis, and Eidos if they can eventually gain approval for their drugs in it too. Unseating entrenched first movers can be difficult.

But the fact that Pfizer is paving the way could also benefit the smaller companies, because TTR-mediated cardiomyopathy (ATTR-CM) is under-diagnosed. "Our early disease awareness efforts have helped drive the diagnosis rates to greater than 4% in the quarter compared with 1% prior to the launch," CEO Albert Bourla said on the third-quarter conference call.

Angela Hwang, president of Pfizer's biopharmaceuticals group laid out how the company is going about helping doctors diagnose the disease: "We have been intensely focused on our educational efforts to help physicians suspect the disease, and this has been helped by the recently published red flag symptoms, which make it easier for physicians to see the possible clinical symptoms of ATTR-CM and helping them to drive suspicion of this disease. From there, we have been educating around the use of scintigraphy as a noninvasive means to diagnose ATTR-CM."

Clearly, Pfizer is putting in a lot of the legwork that will be required to expand the market, and it has a ways to go before it gets the lion's share of affected patients properly diagnosed.

If one or more of the smaller companies can show their drug(s) work better than Vyndaqel, they'll have a shot at taking market share from Pfizer. And, more importantly, the market is likely to be substantially larger thanks to Pfizer's educational efforts.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.95 (0.34%) $0.17
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
$46.11 (4.18%) $1.85
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$232.00 (3.86%) $8.63
Akcea Therapeutics, Inc. Stock Quote
Akcea Therapeutics, Inc.
Eidos Therapeutics, Inc. Stock Quote
Eidos Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.